Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Thermo Fisher Scientific Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Short-term obligations and current maturities of long-term obligations 3,609 5,579 2,537 2,628 676
Accounts payable 2,872 3,381 2,867 2,175 1,920
Accrued payroll and employee benefits 1,596 2,095 2,427 1,916 1,010
Contract liabilities 2,689 2,601 2,655 1,271 916
Other accrued expenses 3,246 3,354 2,950 2,314 1,675
Current liabilities 14,012 17,010 13,436 10,304 6,197
Deferred income taxes 1,922 2,849 3,837 1,794 2,192
Other long-term liabilities 4,642 4,238 4,540 3,330 3,241
Long-term obligations, excluding current maturities 31,308 28,909 32,333 19,107 17,076
Long-term liabilities 37,872 35,996 40,710 24,231 22,509
Total liabilities 51,884 53,006 54,146 34,535 28,706
Redeemable noncontrolling interest 118 116 122
Preferred stock, $100 par value; none issued
Common stock, $1 par value 442 441 439 437 434
Capital in excess of par value 17,286 16,743 16,174 15,579 15,064
Retained earnings 47,364 41,910 35,431 28,116 22,092
Treasury stock at cost (15,133) (12,017) (8,922) (6,818) (5,236)
Accumulated other comprehensive loss (3,224) (3,099) (2,329) (2,807) (2,679)
Total Thermo Fisher Scientific Inc. shareholders’ equity 46,735 43,978 40,793 34,507 29,675
Noncontrolling interests (11) 54 62 10
Total equity 46,724 44,032 40,855 34,517 29,675
Total liabilities, redeemable noncontrolling interest and equity 98,726 97,154 95,123 69,052 58,381

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Thermo Fisher Scientific Inc. current liabilities increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Thermo Fisher Scientific Inc. long-term liabilities decreased from 2021 to 2022 but then slightly increased from 2022 to 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Thermo Fisher Scientific Inc. total liabilities decreased from 2021 to 2022 and from 2022 to 2023.
Total Thermo Fisher Scientific Inc. shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Thermo Fisher Scientific Inc. total Thermo Fisher Scientific Inc. shareholders’ equity increased from 2021 to 2022 and from 2022 to 2023.